for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioGaia AB

BIOGb.ST

Latest Trade

383.00SEK

Change

1.00(+0.26%)

Volume

104,091

Today's Range

375.50

 - 

385.00

52 Week Range

309.00

 - 

479.00

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
382.00
Open
381.50
Volume
104,091
3M AVG Volume
0.32
Today's High
385.00
Today's Low
375.50
52 Week High
479.00
52 Week Low
309.00
Shares Out (MIL)
17.34
Market Cap (MIL)
6,547.04
Forward P/E
32.97
Dividend (Yield %)
2.53

Next Event

Q3 2019 Biogaia AB Earnings Release

Latest Developments

More

Biogaia Says Estimates Delays To Affect Sales To Distribution Partners, Earnings In Both Q3 & Q4

Biogaia Q2 Operating Profit At SEK 78.5 Million

Biogaia Signs Exclusive Agreement In Uruguay

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioGaia AB

Biogaia AB is a Sweden-based company engaged in the development and sell of probiotic products, primarily based on the Lactobacillus reuteri bacteria. The Company’s activities are divided into three segments: Finished consumer products, which distributes tablets, drops, Oral Rehydration Solutions (ORSs), and oral health products, among others; Component products, which is responsible for the sale of LifeTop Straw and Life Top Cap, as well as of cultures as an ingredient in licensee products, such as infant formula and dairy products; and Other products, including animal health goods. It collaborates with Nestle, Gerber, Delta Medical, InfectoPharmm, Ferring Middle East, AllergyCare, and Ewopharma, among others. Furthermore, the Company operates worldwide through a number of subsidiaries, such as Biogaia Biologics Inc, CapAble AB, TwoPac AB and Infant Bacterial Therapeutics AB.

Industry

Food Processing

Contact Info

Kungsbroplan 3

+46.8.55529300

https://www.biogaia.se/

Executive Leadership

Peter Rothschild

Chairman of the Board

Isabelle Ducellier

Chief Executive Officer

David E. R. Dangoor

Independent Vice Chairman of the Board

Peter Persson

Managing Director of BioGaia Production AB

Margareta Hagman

Executive Vice President Accounting, Finance and Investor Relations

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2016

0.5K

2017

0.6K

2018

0.7K

2019(E)

0.8K
EPS (SEK)

2016

13.130

2017

10.420

2018

12.400

2019(E)

11.965
Price To Earnings (TTM)
33.32
Price To Sales (TTM)
8.42
Price To Book (MRQ)
16.42
Price To Cash Flow (TTM)
30.26
Total Debt To Equity (MRQ)
5.14
LT Debt To Equity (MRQ)
3.34
Return on Investment (TTM)
47.27
Return on Equity (TTM)
34.52

Latest News

Latest News

BRIEF-Biogaia Q1 operating profit roughly unchanged yr/yr

* BIOGAIA AB Q1 OPERATING PROFIT AMOUNTED TO SEK 56.2 MILLION (56.1) Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Biogaia increases stake in MetaboGen to 62 pct

* Has decided to acquire additional shares in the associated company MetaboGen AB and is now investing SEK 11.7 million in shares in the company.

BRIEF-Biogaia partners with Dr Reddy's for India launch of protectis drops

* BIOGAIA HAS ENTERED INTO A PARTNERSHIP WITH DR. REDDY’S LABORATORIES FOR THE MARKETING AND DISTRIBUTION OF BIOGAIA PROTECTIS DROPS IN THE INDIAN MARKET

BRIEF-Biogaia Q4 profit rises, proposes extra dividend

* Q4 NET SALES AMOUNTED TO SEK 170.1 MILLION VS YR-AGO 138.8 MILLION, AN INCREASE OF 23% (EXCLUDING FOREIGN EXCHANGE EFFECTS, 27%)

BRIEF-Biogaia signs deal with Abbott to launch probiotic in China

* SAYS HAS SIGNED AN EXCLUSIVE AGREEMENT WITH ABBOTT FOR RIGHTS TO COMMERCIALIZE BIOGAIA PROTECTIS TABS IN CHINA

BRIEF-Biogaia Q3 operating profit up 11 pct​

* Biogaia says Q3 net sales amounted to 147.7 million SEK(126.0), up 17 pct

BRIEF-BioGaia Q2 op profit rose to SEK 60 mln

* Q2 net sales amounted to SEK 156.0 million (136.0), an increase of 15% (excluding foreign exchange effects, 10%).

BRIEF-Biogaia Q1 operating profit increases to SEK 56 mln

* Q1 net sales amounted to SEK 141.1 million (133.9), an increase of SEK 7.2 million (5 pct)

BRIEF-Biogaia Q4 adj. operating profit rises 45 pct, lifts margin target

* Q4 operating profit excluding IBT was SEK 46.4 million (32.0)

BRIEF-Swedbank Robur increases Biogaia stake to 7.1 PCT

* Swedbank Robur increases stake to 7.1 percent, a filing from the Shedish FSA shows on Wednesday Further company coverage:

BRIEF-Biogaia's probiotic to be launched in Thailand

* Biogaia has signed an exclusive agreement with Abbott for the rights to commercialize Biogaia products in the area of paediatrics and gastroenterology in Thailand Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Biogaia Q3 operating profit increases

* Biogaia q3 operating profit excluding IBT was SEK 48.4 million (36.2) Source text for Eikon: Further company coverage: (Reporting By Johan Ahlander)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up